Jun 19, 2008 - AVANIR Pharmaceuticals today announced that the European Patent Office (EPO) has granted AVANIR a new patent, extending the period of commercial exclusivity for its lead drug candidate Zenvia(TM) (dextromethorphan/quinidine) into 2023.
EPO patent number 1.539.166 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" will be published in the European Patent Bulletin on July 2, 2008 and will be effective on that date. The new European patent expands the available Zenvia dose ranges under prior patent protection and encompasses the Company's current clinical development programs in pseudobulbar affect (PBA) and diabetic peripheral neuropathic (DPN) pain, as well as other neurologic conditions.
The details can be read here.
No comments:
Post a Comment